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1. Introduction 
1.1. Plasma glucose levels and prediction of future type 2 diabetes 
Prediabetes (PD) is a dysmetabolic state of glucose level between diabetes mellitus and 
normal glucose tolerance (NGT) which includes basically impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT). All these conditions are becoming a considerable public 
health problem worldwide [1]. Measurement of glucose in plasma of fasting subjects is 
widely accepted as a diagnostic criterion for diabetes. Oral glucose tolerance test (OGTT) 
evaluates the efficiency of the body to metabolize glucose. For many years, fasting plasma 
glucose (FPG) test and OGTT have been used as “gold standards” for diagnosis of glucose 
metabolism disorders [2]. In addition hemoglobin A1C (HbA1C) measurement has also 
become the focus of considerable attention for diagnosis of diabetes. HbA1C is formed by 
the nonenzymatic attachment of glucose to the N-terminal valin of the beta chain of 
hemoglobin and its normal range is between 4% and 6% [2-4]. Because of the long life span 
of erythrocytes, HbA1C reflects long-term glycemic exposure, representing the average 
glucose concentration over the preceding 8-12 weeks [2].  
The hyperglycemic diagnostic criteria defined by American Diabetes Association (ADA) is 
widely used for the evaluation of glucose metabolism disorders [1]. Fasting plasma glucose 
(FPG) is less than 100 mg/dl and 2-hour postprandial plasma glucose (2hPG) [75g glucose 
OGTT) level is less than 140 mg/dl in normal glucose tolerance (NGT). If the FPG level is 
between 100 and 125 mg/ dl, but the 2hPG level is less than 140 mg/dl, this situation is 
defined as IFG. In IGT, the FPG level is between 100 and 125 mg/ dl, the 2hPG level is 
between 140 and 200 mg/dl. If 2hPG level is more than 200 mg/dl, it is termed as diabetes 
according to the ADA’s criteria [1,2]. Similarly, the glycated hemoglobin (HbA1c) level is 
found more than 6.5% in type 2 diabetes [1,2].  
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There are some fundamental problems in using IGT and IFG to characterize abnormal 
glucose metabolism. These problems can be classified as; the best means of identifying 
at-risk populations, whether they characterize the same degree of risk, and whether IFG 
and IGT represent manifestations of the same process or fundamentally different 
mechanisms [5].  
The results of recent studies demonstrate that, although both IFG and IGT are characterized 
by ß-cell dysfunction, the defects in insulin secretion in IFG and IGT are very distinct [6]. 
Subjects with IGT have impaired late-phase insulin secretion and increased insulin 
resistance (IR) in skeletal muscle. In contrasts, subjects with IFG have impaired early –phase 
insulin secretion and increased IR in liver [6-8]. Similarly there are some discrepancies 
between the clinical features of IFG and IGT. Subjects with isolated IFG are more insulin 
resistant, and subjects with isolated IGT exhibits a more severe deficit in insulin secretion 
[8]. IFG and IGT have been associated with other features of insulin resistance, including 
dyslipidaemia, hypertension, abdominal obesity, microalbuminuria, endothelial 
dysfunction, and markers of inflammation and hypercoagulability [5]. Combinations of 
these components have also been associated with progression to type 2 diabetes mellitus 
(T2DM), cardiovascular disease and increased mortality [10].  
Impaired ß-cell function and increased IR in several peripheral tissues are both present in 
type 2 diabetes mellitus (T2DM) [9]. Currently it is understood that T2DM is also associated 
with obesity, hypertension and combined hyperlipidemia [10-12]. Populations at high risk 
for development of T2DM and atherosclerosis can be identified using markers of abnormal 
glucose metabolism, and recent studies have demonstrated that lifestyle modification and 
some pharmacological therapies have a favorable effect on reducing the risk for 
development of T2DM and increased mortality [5,10].  
2. Relationship between obesity and glucose metabolism  
Obesity is associated with an array of health problems including IR and T2DM, fatty liver 
disease, atherosclerosis, airway diseases, degenerative disorders, and various types of 
cancer [11,12]. IR is determined by impaired insulin sensitivity of its main target organs, 
such as adipose tissue, liver, and muscle. Insulin regulates glucose uptake and circulating 
free fatty acid (FFA) concentrations. Insulin decreases lipolysis in adipose tissue and inhibits 
gluconeogenesis in liver. Insulin resistance leads to increased circulating FFA concentrations 
and ectopic fat accumulation that impede insulin mediated glucose uptake in skeletal 
muscle and elevated glucose production in liver [13]. Finally, IR together with abnormalities 
in insulin secretion leads to T2DM [13].  
Obesity is defined as abnormal or excessive fat accumulation and it is measured with body 
mass index (BMI) [10]. The conceptual transformation of adipose tissue from a passive 
organ to an active participant of homeostasis, has emerged relatively recently [12,14]. In 
1994, adipose tissue was identified as the source of the hormone leptin, opening the door for 
a new area of research focused on adipocyte endocrinology [14]. Our understanding of the 
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pathogenesis of obesity and its metabolic disturbances have advanced significantly over the 
past decades [11-14]. The growing evidence on obesity and associated pathologies has led to 
understand the role of adipose tissue as an active potential participant in controlling the 
physiological and pathological processes [11-15]. For many years, adipose tissue was 
regarded merely as a heat insulator and a store of excess FFAs that could be released when 
needed [14]. To date, the adipose tissue is considered as an endocrine organ able to mediate 
biological effects on metabolism and inflammation, contributing to the maintenance of 
energy homeostasis and, probably, pathogenesis of obesity-related metabolic and 
inflammatory complications [10-16]. Nowadays, worldwide increased obesity prevalence 
has been accompanied by a parallel rise in the glucose metabolism disorders [11,17]. There is 
evidence that IR and T2DM is also related to a chronic low-grade inflammatory state [17]. 
Therefore weight loss is associated both with an improvement of the inflammatory profile 
and a decreased risk of glucose metabolism disorders [9-11,13-15]. 
3. Effects of inflammatory mediators on glucose metabolism 
Many complex signaling pathways regulate chronic low-grade inflammation associated 
with both the metabolism and immune systems [18]. Pro- inflammatory cytokines are 
mediators of these pathways and they enter the circulation as a result of lipolysis [10]. 
Recent data indicates that macrophages in adipose tissue are a major source of them [10-18]. 
Especially in obesity, adipose tissue is characterized by an increased production and 
secretion of a wide range of pro- inflammatory molecules which have been recognized as an 
active participant in numerous immunologic processes [13-16]. Cytokines play the crucial 
roles in many physiological and pathological processes such as hematopoiesis, angiogenesis, 
inflammation, atherosclerosis, allergy and autoimmunity [18]. The increased concentrations 
of circulatory cytokines are commonly determined in cardiovascular disease (CVD), the 
metabolic syndrome and T2DM. These cytokines are produced by different cell types and 
are secreted into circulation where they regulate different tissues through their local, central 
or peripheral action [19]. 
It is demonstrated that increases of these cytokines effect through intracellular signaling 
pathways which involve the nuclear factor kappa B (NF- κB) and c- Jun N-terminal 
kinase (JNK) systems [10]. Leptin also impairs glucose-stimulated insulin production of 
human β cells through activation of JNK. Moreover, hyperglycemia induces IL-1β 
production by pancreatic β-cells, which putatively contributes to glucotoxicity in human 
pancreatic islets [13]. 
The name of adipokine is nowadays generally given to any protein or cytokine that can be 
synthesized and secreted by adipocytes [11]. Several studies have shown that adipokine 
production is altered in obesity [11]. The first link between obesity and elevation of Tumor 
Necrosis Factor- Alpha (TNF-α) came from a study almost 20 years ago and this finding led 
to the concept of inflammation in obesity and demonstrated that adipocytes express TNF-α 
[17-23]. TNF-alpha is a pro- inflammatory cytokine, overproduced in adipose tissue of 
several rodent models of obesity and has an important role in the pathogenesis of IR in these 
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species [21]. Interleukin-1 (IL-1) is one of the first identified cytokines and exert strong pro-
inflammatory functions [10,20]. IL-1α has been demonstrated to be involved in the 
pathogenesis of glucose metabolism disorders in mice [18]. IL-1β is able to reduce IRS-1 
expression at a transcriptional level through a mechanism that is ERK dependent and at a 
posttranscriptional level independent of ERK activation [18]. By targeting IRS-1, IL-1β is 
capable of impairing insulin signaling and action and could thus participate, in the 
development of IR, in concert with other cytokines [18-21]. IL-6 is also among the first 
identified cytokines and acts on the liver to stimulate the production of a number of acute-
phase proteins [10]. It is implicated as a pathogenetic marker of IR and CVD. IL-1ß together 
with IL-6 concentration is suggested as a predictor for T2DM in humans better than either 
cytokine alone [9,19,23-28].  
Similarly interleukin 8 (IL-8) is a pro- inflammatory cytokine, overproduced in adipose 
tissue of several rodent models of obesity and has an important role in the pathogenesis of 
IR in these species [12,21,29,30]. However, IL-8 is basically evaluated as a cytokine with 
atherogenic properties and its actual involvement in glucose metabolism disorders remains 
controversial in humans [29-31]. Through its multiple actions, IL-8 might promote intimal 
thickening and atherosclerosis. This cytokine is also able to increase the instability of 
atherosclerotic plaque [29-31]. Elevated circulating IL-8 levels were also reported in type 1 
and type 2 diabetic patients. It was hypothesized that this cytokine could be involved in the 
pathogenesis of diabetic macroangiopathy. Especially T2DM is associated with accelerated 
atherogenesis and it is recognized as an independent risk factor for CVD. Precise 
mechanisms linking those conditions are not fully understood [18,19]. In recent years, 
theories about the role of chronic low-grade inflammation in the pathogenesis of both 
glucose metabolism disorders and atherosclerosis have been developed. Some 
investigations reported that elevated plasma IL-8 concentrations are related to obesity and 
hyperlipidemia [12].  
C-reactive protein (CRP) is an acute-phase reactant, the elevation of which is indicative of 
acute or chronic inflammation [32,33]. CRP is produced solely by the liver [19]. An 
etiologic role for chronic inflammation in the development of IR has been hypothesized 
[32,33]. It has been recognized that elevation of CRP concentrations is an independent 
predictive parameter of T2DM, which is also associated with various components of the 
metabolic syndrome such as obesity, IR, and dyslipidemia [20-24]. A number of previous 
study have reported that high sensitivity (hs) CRP is also related to circulating IL-6 levels 
[24,32,33] and IL-6 is a powerful inducer of CRP production in the liver [18]. In addition, 
abdominal obesity is associated with elevated plasma hs-CRP concentration and it has 
shown that elevation of hs-CRP concentration is an independent predictive parameter of 
T2DM [32,33] Actually CRP is a most sensitive marker of inflammation and it is associated 
with features of IR [15,16].  
More recently, hormone leptin has also been linked to inflammation in human. Leptin, is the 
product of the ob gene. It is involved in the regulation of energy homeostasis and is almost 
exclusively expressed and produced by white adipose tissue (WAT) and more particularly 
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by differentiated mature adipocytes [11]. Circulating levels and adipose tissue mRNA 
expression of leptin are strongly associated with BMI and fat mass in obesity. Therefore, 
leptin appears as a real marker of adipose tissue mass in humans [11]. Leptin acts mainly at 
the level of the central nervous system to regulate food intake and energy expenditure. In 
addition, there is a relationship between leptin and the low-grade inflammatory state in 
obesity. It was suggested that leptin could exert peripheral biological effects as a function of 
its cytokine-like structure. It is similar to the IL-2 and receptors of leptin belong to the 
cytokine class I receptor family [14]. Some works have reported that there is an increased 
inflammatory response associated with the presence of hyperleptinemia without obesity. 
Leptin-deficient mice or humans display an altered immune status . The reduction in leptin 
levels could be responsible for fat-associated immunosuppression [11]. Leptin is able to 
control TNF-α production and activation by macrophages, however, the underlying 
mechanisms have not been clearly identified [11,14].  
Adiponectin is an adipokine mainly produced by the adipose tissue and it is induced by 
activity of the nuclear peroxisome- proliferator–activated receptor (PPAR) γ. It exists both as 
a full-length protein as well as a proteolytic cleavage fragment, also known as globular 
adiponectin. Adiponectin circulates at high concentrations in human serum [5 to 10 μg/mL) 
and has a wide spectrum of biological activities. Adiponectin is unique that, unlike other 
adipokines, circulating concentrations are reduced with obesity. Serum levels of adiponectin 
are reduced in individuals with visceral obesity and states of IR. TNF-α suppresses the 
transcription of adiponectin in adipocytes, which might explain the lower adiponectin levels 
in serum in individuals who are obese. Weight loss induces adiponectin synthesis, as 
activation of PPARγ by its ligands thiazolidinediones (TZDs), which are used in the 
treatment of T2DM [19,21]  
Data from epidemiological studies indicate that circulating adiponectin is reduced in 
patients with CVD and T2DM. Importantly, low adiponectin concentrations are strongly 
correlated with IR. In addition, adiponectin reduces glucose production in the liver by 
directly inhibiting the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and 
glucose 6 phosphate , improving glycemic control and insulin sensitivity .The reduction in 
adiponectin with obesity and diabetes most likely arises from increased adipose tissue 
macrophage infiltration resulting in inflammation. In contrast, high concentrations of 
adiponectin are related to higher insulin sensitivity and decreased risk for CVD. The 
proinflammatory cytokines TNFα and IL-6 reduce adiponectin expression. Conversely, 
adiponectin has an antiinflammatory effect, inhibiting activation of NFκB by TNFα [19].  
Resistin, also called FIZZ3 (found in inflammatory zones) or adipocyte secreted factor 
(ADSF) has been discovered in 2001 while looking for new molecular targets of TZDs in 
adipocytes [11,33]. It was shown that resistin levels were increased in obese rodents and 
resistin knock-out mice have lower fasting glycaemia, increased glucose tolerance and 
insulin sensitivity associated with a reduced liver glucose production [11]. Resistin is also 
expressed in the WAT, especially in the WAT of abdominal region and female gonadal 
adipose tissue [33]. Resistin has been linked with many facets of the metabolic syndrome, 
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principally, obesity, insulin resistance and hyperlipidemia. The effect of resistin upon 
insulin resistance is mediated through increased expression of suppressor of cytokine 
signaling-3 (SOCS-3], which is a known inhibitor of insulin signaling [33]. Mice injected with 
resistin showed insulin resistance. Resistin was thus found to attend endocrine functions 
that led to insulin resistance. Increased expression of resistin was found to be associated 
with dyslipidemia and non-alcoholic fatty liver disease (NAFLD) in a few medical ranks. In 
patients with NAFLD, serum resistin levels were higher than those in control cases. The 
presence of metabolic syndrome with elevated levels of plasma resistin is associated with 
increased cardiovascular risk [33-35]. 
Osteopontin (OPN) actually is a secreted matrix glycoprotein and pro-inflammatory 
cytokine playing an important role in cell-mediated immunity. Its ability to interact with 
integrin surface molecules through an Arg-Gly-Asp sequence and with the CD44 receptor 
has established this mediator as an important signaling molecule [34]. Indeed, tissue 
infiltration of macrophages as observed in obesity is dependent on the expression of OPN, 
which promotes monocyte chemotaxis and motility. Obese mice lacking OPN showed 
improved insulin sensitivity and decreased macrophage infiltration into adipose tissue. 
These experiments add OPN to a long list of pro-inflammatory pathways involved in the 
development of IR [21] 
However, actual involvement of all these mediators in glucose metabolism disorders in 
humans remains controversial. It is suggested that these mediators may alter insulin 
sensitivity by triggering different key steps in the insulin signaling pathway and 
overproduction of them is associated with the glucose metabolism disorders [36-40]. Many 
mediators contribute to the pathogenesis of impaired glucose homeostasis and most of them 
are overproduced during obesity. It now appears that obesity is associated with a low- 
grade inflammation of adipose tissue, resulting from activation of innate immune system. 
Especially in obesity, adipose tissue is characterized by an increased production and 
secretion of a wide range of pro- inflammatory molecules including IL-1ß, IL-6, IL-8, TNF-α, 
CRP, leptin, resistin and so on [23-35]. Recent data indicate that macrophages in obese 
adipose tissue are major source of most mediators. Therefore weight loss is associated with a 
reduction in the macrophage infiltration of adipose tissue and an improvement of the 
inflammatory profile [39-45].  
4. Conclusion 
During the last decades, understanding of the biology of adipose tissue and especially its 
secretory functions, have dramatically improved. This development has completely 
modified the understanding of the pathogenesis of obesity, glucose metabolism disorders 
and inflammation. Several cytokines attracted considerable attention as potential effectors in 
the pathology and physiology of insulin resistance associated with type 2 diabetes mellitus 
(T2DM) and obesity. Recent studies have implicated a number of inflammatory mediators 
including cytokines and adipokines in the inflammatory responses that accompany the 
glucose metabolism disorders. Therefore measurement of serum levels of inflammatory 
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mediator is important in determining glucose regulation disorders and provides an 
improvement in therapeutic approaches to modulate the inflammatory responses and 
thereby alter disease progression. Elucidation of the mechanisms that link obesity with 
inflammation and glucose metabolism will contribute to the understanding of the 
physiopathology of obesity. As well as it will be probably provide the new strategies in the 
development of new therapeutic approaches.  
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